enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Accelerate Bladder Cancer Gene Therapy Development
核心洞察
enGene's detalimogene voraplasmid has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, one of only nine companies awarded annually.
The program aims to facilitate manufacturing readiness for therapies with compressed clinical development timeframes, supporting enGene's planned BLA submission in the second half of 2026.
Detalimogene is a non-viral gene therapy targeting high-risk, non-muscle invasive bladder cancer patients who are unresponsive to standard BCG treatment and face potential bladder removal.
enGene Holdings Inc (搜索). announced that the U.S. Food and Drug Administration has selected detalimogene voraplasmid for participation in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program. The selection positions enGene among only nine companies awarded CDRP participation annually, supporting the development of its investigational non-viral gene therapy for high-risk, non-muscle invasive bladder cancer.
Manufacturing Readiness Strategy
The CDRP Program was created by the FDA to facilitate CMC development for therapies with compressed clinical development timeframes, based on the anticipated clinical benefits of earlier patient access. The initiative promotes earlier and more structured engagement between sponsors and FDA on CMC development strategies, enabling sponsors to confidently scale up manufacturing capacity while clinical development continues.
"Manufacturing readiness in drug development is often underappreciated. We have already scaled detalimogene manufacturing to commercial-level, and CDRP is expected to help ensure CMC readiness for filing and commercialization," said Ron Cooper, President and Chief Executive Officer of enGene. The company has already manufactured detalimogene at commercial scale, with the CDRP providing additional FDA CMC interactions ahead of a potential BLA submission planned for the second half of 2026.
Addressing High Unmet Medical Need
Non-muscle invasive bladder cancer represents a significant clinical burden, with approximately 75%-80% of new bladder cancer diagnoses falling into this category. The disease occurs when cancer cells grow in the tissues lining the bladder interior but have not penetrated the muscle wall. NMIBC can present as papillary outgrowths or as carcinoma in situ, consisting of flat, multifocal lesions that cannot be resected.
Patients with high-risk NMIBC who are unresponsive to the standard of care, Bacillus Calmette-Guérin (BCG), face particularly challenging outcomes. These patients experience high rates of disease recurrence ranging from 50%-70% and are potentially subject to complete bladder removal (cystectomy) as a curative but life-altering treatment option.
Regulatory Recognition and Clinical Development
Detalimogene has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, recognizing its potential to address the high unmet medical need for patients with BCG-unresponsive, carcinoma in situ NMIBC with or without resected papillary tumors who are unable to undergo cystectomy.
The RMAT program is designed to expedite development and review of regenerative medicine therapies for serious or life-threatening conditions where preliminary clinical evidence suggests potential to address unmet medical needs. Fast Track designation facilitates development and expedites review of drugs treating serious conditions with unmet medical needs.
LEGEND Trial Progress
Detalimogene is currently being evaluated in the ongoing, open-label, multi-cohort Phase 2 LEGEND trial to establish safety and efficacy in high-risk NMIBC. The trial's pivotal cohort (Cohort 1) consists of 125 patients with high-risk, BCG-unresponsive NMIBC with CIS, with or without papillary disease, designed to serve as the basis for the company's planned Biologics License Application filing.
Cooper noted recent progress in clinical development, stating that the company "recently announced improved six-month complete response rate in the LEGEND trial pivotal cohort." The LEGEND trial includes three additional cohorts beyond the pivotal group, studying various patient populations including BCG-naïve patients and those with papillary-only disease.
Platform Technology
Detalimogene was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of various cargo types, including DNA and RNA. The company positions itself as a clinical-stage biotechnology company focused on mainstreaming genetic medicines through delivery to mucosal tissues and other organs.